Collaborative webinar: economic modelling in rare diseases

Mar 2, 2021

Watch the recording

 

It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust data to minimise uncertainty.

This webinar introduces a new approach in which multiple companies collaborate to develop a core economic model and common data set. An approach that aims to optimise HTA and reimbursement outcomes for all new treatments in a rare disease.

Speakers: Prof. Keith Abrams, Prof. John Brazier, Dr. Jill CarltonJosie GodfreyJamie O’Hara, Dr Mark Larkin, PhD, and Juliet Mumby-Croft

JG ZEBRA CONSULTING LTDHCD Economics LtdUniversity of LeicesterUniversity of YorkThe University of SheffieldVitaccessSource Health Economics.

#ProjectHERCULES #rarediseases #heor #healtheconomics #evidencebasedmedicine #pharmaceuticalindustry

More Insights

Conceptual modelling and NICE requirements: a significant change or hill of beans?

Conceptual modelling and NICE requirements: a significant change or hill of beans?

Written by Alec Miners, Head of Health Economics The National Institute for Health and Care Excellence’s (NICE’s) new processes and methods guide includes several important changes to the way submitted economic evaluations should be conducted ... Read more

British Heart Week 2022

British Heart Week 2022

As we approach the end of British Heart Week, we reflect on some of the key stats around heart conditions in the UK and our contribution as a company to help bring cutting-edge treatments to patients with cardiovascular diseases Read more

Patient Participation Groups: A voice for patients for 50 years

Patient Participation Groups: A voice for patients for 50 years

Written by Dom Partridge, Medical Writer 6th to 13th June 2022 is Patient Participation Group (PPG) Awareness Week; aiming to raise the profile of PPGs within primary healthcare. The first Patient Participation Group The first PPG was set up in ... Read more

The Innovative Medicines Fund is now available to fast-track non-cancer medicines recommended with managed access

The Innovative Medicines Fund is now available to fast-track non-cancer medicines recommended with managed access

The Innovative Medicines Fund (IMF) launched this month (June 2022) to support faster access to non-cancer drugs. This process involves NHS England and the National Institute for Health and Care Excellence (NICE) working in partnership with ... Read more